Compounded semaglutide vs Wegovy: 2026 buyer's guide

TL;DR

For each dimension where one drug clearly wins, we name the winner. When the answer is "depends on your situation," the verdict text below the table explains why.

Dimension	What the data says	Winner
Active ingredient	Semaglutide in both	Tie
FDA approval as drug product	Wegovy yes; compounded no	Wegovy
Cash-pay cost	$178/mo floor (compounded, Mochi month-to-month) vs $149/mo pill or $199/mo injection intro (NovoCare)	Compounded
Insurance coverage	Wegovy with PA; compounded never covered	Wegovy
Supply continuity in 2025-2026	Wegovy stable; compounded semaglutide narrowed but holding	Wegovy
Manufacturing oversight	FDA cGMP for Wegovy; state-board oversight for 503A	Wegovy
Prescriber access	Most US weight loss telehealth programs prescribe both	Tie

Verdict

If you can access Wegovy through insurance with prior authorization, choose Wegovy. The full FDA oversight, manufacturing consistency and stable supply chain are worth the trade against compounded's lower cash price. If you cannot access insurance and NovoCare's pricing doesn't fit your budget, compounded semaglutide via a transparent 503A program (Mochi, Noom Med microdose) is a defensible second choice. The molecule is the same; the regulatory pathway is not.

Trial efficacy compared

The headline numbers are not from the same study, so direct comparison is approximate.

	Compounded semaglutide	Wegovy
Registration trial	STEP-1 (parent molecule, Wegovy) (NEJM, 2021)	STEP-1 (NEJM, 2021)
Duration	68 weeks	68 weeks
Mean weight loss (max dose)	14.9%	14.9%
Effect vs comparator	12.4 pp vs placebo	12.4 pp vs placebo
Patients losing ≥5%	86.4%	86.4%
Patients losing ≥15%	50.5%	50.5%

2026 cash-pay cost compared

Both have a direct cash channel (telehealth programs for Compounded semaglutide, NovoCare for Wegovy) that is dramatically cheaper than the retail pharmacy cash price. Telehealth programs add a membership fee on top of medication cost.

Channel	Compounded semaglutide	Wegovy
Retail cash	Not sold at retail; cash-pay through telehealth programs only	$1,349/mo
Manufacturer DTC	$169-$199/mo via telehealth programs (Mochi $178 flat month-to-month, Found $169 on a 12-month plan, Noom microdose $199). Strut Health at $99 is an oral lozenge, not an injectable.	$149/mo pill (starter dose) or $199/mo injection intro (through 6/30/26 then $349) / $299 maintenance via NovoCare
With insurance + PA	Not covered by insurance. Compounded medications are not eligible for insurance reimbursement as drug products.	$25-$50/mo with prior authorization
Compounded	Cash-pay only by definition. Pricing varies from $169/mo (Found, 12-month commitment) and $178/mo month-to-month (Mochi) up to $299/mo depending on program.	$175-$199/mo via 503A pharmacies

When to choose Compounded semaglutide

Choose compounded semaglutide if: (1) you have no insurance coverage and NovoCare's lowest tier is still out of reach for your budget; (2) you have selected a program with a transparent and stable 503A pharmacy partnership (Mochi or Noom microdose are the cleanest in our chart); (3) you understand the regulatory environment may tighten further; (4) you have a Plan B if the program loses pharmacy partnership mid-treatment.

When to choose Wegovy

Choose Wegovy if: (1) your insurance covers it (most commercial plans do for BMI ≥30 with PA); (2) NovoCare's $149/mo pill or $199/mo injection intro is within budget; (3) you want manufacturing oversight under FDA cGMP rather than state-board oversight; (4) you want supply continuity that doesn't depend on a single 503A pharmacy partnership; (5) you want the option to switch programs without changing medication source.

Programs that prescribe each

Some visit links earn us a commission.

Top Compounded semaglutide programs

Top Wegovy programs

FAQ

Is compounded semaglutide the same as Wegovy?

Same active molecule (semaglutide); different regulatory pathway. Wegovy is FDA-approved as a drug product manufactured under cGMP by Novo Nordisk. Compounded semaglutide is prepared by a 503A pharmacy under individual prescription, not FDA-approved as a drug product. The molecules are chemically identical; the manufacturing oversight, supply chain and regulatory standing are not.

Is compounded semaglutide legal?

Yes, under section 503A of the Federal Food, Drug and Cosmetic Act, when prepared for an individual patient under valid prescription. Compounding existed before GLP-1s and serves a legitimate role in drug supply (allergies to inactive ingredients, dosing adjustments, etc.). The category-wide volume of compounded GLP-1 has prompted increased FDA enforcement attention since the semaglutide shortage was declared resolved in October 2024.

Will my insurance cover compounded semaglutide?

Almost never. Compounded medications are not eligible for insurance reimbursement as drug products in the way FDA-approved drugs are. A small number of insurance plans reimburse compounded medications under their compounding benefit, but GLP-1 specifically is rarely covered.

What if my program's compounded supply is cut off?

This is the central practical risk in 2026. Programs vary in their continuity planning. The cleanest programs have multiple 503A partnerships; some are pre-positioning patients to switch to NovoCare or Wegovy if compounded supply ends. Ask your program directly about Plan B before committing.

Can I switch from compounded to Wegovy mid-treatment?

Yes. Most prescribers will continue you on the same dose level (e.g., compounded 1.0mg to Wegovy 1.0mg) and titrate from there. The switch is straightforward clinically; the friction is administrative (insurance PA, program enrollment) and budgetary (Wegovy with insurance is typically much cheaper than compounded; without insurance, NovoCare may be more or less depending on dose tier).

Read the full drug profiles

Editorial disclosure

GLP Chart is an editorial comparison site. We do not dispense, prescribe or fulfill medications. Trial data is from the cited NEJM publications. Pricing reflects publicly verified rates as of June 22. Talk to a licensed clinician about which medication is appropriate for you.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this site · LinkedIn · Contact

Why you can trust GLP ChartSame scoring framework applied to every program. No paid placements. We never remove unfavorable information at an advertiser's request. Pricing is pulled from each program's public-facing page every Monday.

Compounded semaglutide vs Wegovy: which weight loss drug is better in 2026?